AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition

64th ASH Annual Meeting and Exposition

Oral presentation of updated safety and efficacy data for AVC-101 in relapsed/refractory acute myeloid leukemia Achieves clinical proof of concept with efficacy signal in late-line r/r AML patients and demonstrates rapid CAR T Cell on-off control mechanism of Universal Targeting platform CAMBRIDGE, Mass.– Nov. 3, 2022–AvenCell Therapeutics, Inc. announced today that expanded data from its […]

AvenCell announces Tapan Maniar as new Chief Medical Officer

Tapan Maniar 900x600px 02

Effective September 2022, we welcomed our newly appointed Chief Medical Officer to the AvenCell Leadership Team – Dr. Tapan Maniar. Tap succeeds Professor Gerhard Ehninger who is moving to our Board of Directors. For more than a decade, Dr. Maniar has spent the majority of his career in the biotechnology space. Joining Amgen in 2012, […]

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

GEMoaBProjectDiamantPRDeutsch210622 1600x900

Focus will be on Development of Allogeneic Universal CAR T-Cell Therapies for Immuno-oncology and Autoimmune Diseases Blackstone Life Sciences Commits to an Active Role and a $250 Million Financing as Sole Founding Investor Cellex to Contribute Switchable Universal CAR-T Technology Developed by GEMoaB GmbH and Manufacturing Expertise Intellia Contributes Best-in-Class CRISPR/Cas9 Genome Editing Technology that […]